Novavax, Inc. (NVAX) Traders See Another Multi-Year High Ahead

Novavax, Inc. (NVAX) calls are trading at seven times the average intraday pace

Feb 17, 2015 at 10:53 AM
facebook twitter linkedin

Novavax, Inc. (NASDAQ:NVAX) tacked on 10.4% last week amid news the company is beginning early stage testing of its Ebola vaccine on humans. The equity is extending this momentum today, up 3% at $9.06 -- after earlier hitting a 12-year peak of $9.23. Options traders are responding in kind, with calls crossing the tape at a rate seven times the intraday average, and outpacing puts by a nearly 19-to-1 margin.

Drilling down, NVAX's March 9 call has seen the most action, with all signs suggesting buy-to-open activity. The volume-weighted average price (VWAP) for the calls is $0.76, making at-expiration breakeven for the call buyers $9.76 (strike plus VWAP) -- which would mark another multi-year high for the shares. Profit will accumulate north of here, while losses are limited to 100% of the premium paid, should NVAX settle south of the strike at the close on Friday, March 20, when the options expire.

From a wider sentiment perspective, today's accelerated call activity marks a change of pace in the equity's options pits. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), for example, NVAX's 10-day put/call volume ratio of 0.19 ranks in the 78th annual percentile. In other words, puts have been bought to open over calls at a faster-than-usual clip in recent weeks.

Looking at the charts, today's optimism among options traders more closely aligns to the equity's technical backdrop. Similar to a number of its sector peers, Novavax, Inc. (NASDAQ:NVAX) has been in rally mode since Ebola began dominating the newswires last October. Specifically, the shares have more than doubled since their Sept. 30 close at $4.17.

Daily Chart of NVAX Since September 2014

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!